Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 12:44:18 29/05/2024 am IST 5-day change 1st Jan Change
151.3 USD -9.18% Intraday chart for Moderna, Inc. +5.16% +51.95%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nasdaq exceeds 17,000 on boost from Nvidia; inflation data awaited RE
Nvidia Rally Drives Nasdaq to Record MT
News Highlights : Top Company News of the Day - Tuesday at 1 PM ET DJ
News Highlights : Top Company News of the Day - Tuesday at 11 AM ET DJ
News Highlights : Top Company News of the Day - Tuesday at 9 AM ET DJ
US, European nations consider vaccinating workers exposed to bird flu RE
Novavax awaits FDA decision on whether its next COVID shot can be offered in US RE
Global markets live: Anglo American, Nvidia, Apple, Amazon, Tesla, Walt Disney... Our Logo
The market is good to go until Nvidia’s next quarterly results Our Logo
News Highlights : Top Company News of the Day - Thursday at 9 AM ET DJ
News Highlights : Top Company News of the Day - Thursday at 3 AM ET DJ
News Highlights : Top Company News of the Day - Thursday at 1 AM ET DJ
News Highlights : Top Company News of the Day - Wednesday at 11 PM ET DJ
News Highlights : Top Company News of the Day - Wednesday at 9 PM ET DJ
Health Care Up as Vaccine Makers Gain - Health Care Roundup DJ
News Highlights : Top Company News of the Day - Wednesday at 5 PM ET DJ
US IS IN 'ACTIVE CONVERSATIONS' WITH MRNA VACCINE MAKERS PFIZER… RE
Moderna Insider Sold Shares Worth $1,909,863, According to a Recent SEC Filing MT
Moderna Insider Sold Shares Worth $1,912,350, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Sector Update: Health Care Stocks Softer Friday Afternoon MT
Sector Update: Health Care MT
Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech MT
Moderna Wins European Patent Ruling in Covid-19 Vaccine Dispute With Pfizer, BioNTech MT
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program MT
Chart Moderna, Inc.
More charts
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
166.6 USD
Average target price
138.5 USD
Spread / Average Target
-16.86%
Consensus
  1. Stock Market
  2. Equities
  3. MRNA Stock
  4. News Moderna, Inc.
  5. Moderna : Says New Study Shows Its COVID-19 Vaccine Maintains Protection Against Key Variants Through Six Months